Psychiatric problems in patients infected with hepatitis c before and during antiviral treatment with interferon-alpha: A review

Journal of Psychiatric Practice

Volumn 15, Issue 4, 2009, Pages 262-281

  Quelhas, Rosa ^a   Lopes, Alice ^b  

^a Hospital de Pedro Hispano   (Portugal)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Consultation liaison psychiatry; Depression; Hepatitis C; Interferon alpha; Neuropsychiatric syndromes; Psychiatric disorders; Substance use disorders

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN E; CITALOPRAM; DOPAMINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; KYNURENINE; MIRTAZAPINE; NEFAZODONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PAROXETINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PIMOZIDE; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; VALPROIC ACID;

ADDICTION; ALCOHOL CONSUMPTION; ALCOHOLISM; ANEMIA; ANHEDONIA; ANTIVIRAL THERAPY; ANXIETY; APATHY; AUTONOMIC NEUROPATHY; BEHAVIOR DISORDER; BIBLIOGRAPHIC DATABASE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN DYSFUNCTION; BRAIN INJURY; BRAIN METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; CORPUS STRIATUM; CYTOKINE PRODUCTION; DELIRIUM; DEPRESSION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ERADICATION THERAPY; FATIGUE; FLUENCY DISORDER; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOMANIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; ILLNESS BEHAVIOR; IMMUNOMODULATION; INFORMATION RETRIEVAL; INTRAVENOUS DRUG ABUSE; IRRITABILITY; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MELANCHOLIA; MEMORY DISORDER; MENTAL DISEASE; MESENCEPHALON; MIXED ANXIETY AND DEPRESSION; MOOD; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NEUROPSYCHIATRY; NEUROTOXICITY; NEUROTRANSMISSION; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRACTICE GUIDELINE; PREVALENCE; PSYCHOEDUCATION; PSYCHOLOGICAL WELL BEING; PSYCHOSIS; RESTLESSNESS; REVIEW; SEROTONINERGIC SYSTEM; SHORT TERM MEMORY; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKING MEMORY;

ALLELES; ANTIVIRAL AGENTS; BRAIN; DOPAMINE; GLUTAMIC ACID; HEALTH EDUCATION; HEPATITIS C, CHRONIC; HUMANS; HYDROCORTISONE; HYPERTHYROIDISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHYROIDISM; INTERFERON-ALPHA; MENTAL DISORDERS; PATIENT COMPLIANCE; PITUITARY-ADRENAL SYSTEM; PREVALENCE; SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 68949190798     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000358313.06858.ea     Document Type: Review

References (168)

1. World Health Organization. Hepatitis C. (Available at: http://www.who.int/topics/hepatitis/en/index.html, accessed April 10, 2009).
2. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report (MMWR) 2008,57(SS02);1-24.
3. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric co-morbidity among hepatitis-C-positive patients. Psycho-somatics 2001;42:411-415
4. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon-alpha, and depression. Hepatology 2000;31: 1207-1211
5. Dwight MM, Knowdley KV, Russo JE, et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000;49:311-317
6. Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006;18:333-338
7. Weissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-1630
8. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cere-brospinal fluid. J Virol 2002; 76:10064-10068
9. Huckans M, Seelye A, Parcel T, et al. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. J Int Neuropsychol Soc 2009;15: 69-82.
10. Schäefer M, Engelbrecht MA, Gut O, et al. Interferon-alpha and psychiatric syndromes: A review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-746
11. Fontana RJ, Schwartz SM, Gebremariam A, et al. Emotional distress during interferon-alpha-2b and rib-avirin treatment of chronic hepatitis C. Psychosomatics 2002;43:378-385
12. Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: Effects on virologic response. Mol Psychiatry 2005;10:332-333
13. Amodio P, De Toni EN, Cavalletto L, et al. Mood, cognition and EEG changes during interferon-alpha treatment for chronic hepatitis C. J Affect Disord 2005;84:93-98
14. Raison CL. Hepatitis Annual Update 2004: Managing psychiatric side effects of interferon. (Available at www.clinicaloptions.com/Hepatitis/ Annual%20Updates/2 003%20Annual%20Update/Modules/ccohep2003-raison/P ages/Page%201.aspx, accessed June 19, 2009).
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon-alpha-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
16. Neves AC, Dickens C, Xavier M. Comorbidity between hepatitis C and depression. Epidemiological and etiopath-ogenic aspects. Acta Med Port 2006; 19:21-28
17. Constant A, Castera L, Quintard B, et al. Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: Relationship with information sources and attentional coping styles. Psychosomatics 2005;46:25-33.
18. Kraus MR, Schäfer A, Csef H, et al. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000;41:377-384
19. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003;160:172-174
20. Fontana RJ, Kronfol Z, Arbor A. The patient's perspective in hepatitis C: Coping with HCV, doctors, adherence, depression. Hepatology 2004;39:903-905
21. Horsmans Y. Interferon-induced depression in chronic hepatitis C. J Antimicrob Chemother 2006;59:711-713
22. Sulkowski MS. Hepatitis Annual Update 2008: New data on currently available HCV therapies and their impact on initial treatment strategies. (Available at www.clinical-careoptions.com/Hepatitis/Annual%20Updates/2008%20 Annual%20Update/Modules/Sulkowski/Pages/Page%201. aspx, accessed June 19, 2009).
23. Ghany MG, Strader DB, Thomas DL, et al. AASLD practice guidelines: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-1374
24. Foster GR, Fried MW, Hadziyannis SJ, et al. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol 2007;42:247-255
25. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960
26. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/rib-avirin. J Hepatol 2005;43:425-433
27. Lindh M, Alestig E, Arnholm B, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007;45:2439-2445
28. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46: 1688-1694
29. Sanchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131: 451-460
30. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
31. Kraus MR, Schäfer A, Csef H, et al. Compliance with therapy in patients with chronic hepatitis C: Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001;46:2060-2065
32. Hosoda S, Takimura H, Shibayama M, et al. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry Clin Neurosci 2000;54:565-572
33. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947
34. Reichenberg A, Gorman JM, Dieterich D. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS 2005; 19:S174-8.
35. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsy-chiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs 2005;19:105-123
36. Hunt CM, Dominitz JA, Bute BP, et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-2486
37. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002;72: 237-241
38. Dell'Osso L, Pini S, Maggi L, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res 2007;62:349-355
39. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005;66: 41-48
40. Maddock C, Baita A, Orru MG, et al. Psychopharma-cological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: A prospective case series and a discussion of biological mechanisms. Psychopharmacology 2004;18:41-46
41. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-112
42. Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: Prevalence and management. Dig Liver Dis 2005;37:102-107
43. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alpha therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypo-manic and depressive symptoms. J Clin Psychiatry 2005; 66:1050-1057
44. Castera L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006;24: 1223-1230
45. Gohier B, Goeb JL, Rannou-Dubas K, et al. Hepatitis C, alpha-interferon, anxiety and depression disorders; A prospective study of 71 patients. World J Biol Psychiatry 2003 ;4:115-118
46. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42: 793-798
47. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis C undergoing interferon-alpha therapy: A prospective study. Gen Hosp Psychiatry 2003;25:34-38
48. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alpha-2b therapy. J Clin Psychiatry 2003;64: 708-714
49. Otsubo T, Miyaoka H, Kamijima K, et al. Depression during interferon therapy in chronic hepatitis C patients: A prospective study. Seishin Shinkeigaku Zasshi 1997;99: 101-127
50. Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156:1120.
51. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004;365:87-91.
52. Martín-Santos R, Díez-Quevedo C, Castellví P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008;27:257-265
53. Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006;60:77-79
54. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358: 958-965
55. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha-2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004;26:237-240
56. Onyike CU, Bonner JO, Lyketsos CG, et al. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004;161:429-435
57. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon-alpha therapy. Arch Intern Med 1987; 147:1577-1580
58. Scheibel RS, Valentine AD, O'Brien S, et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004;16:2.
59. Meyers CA, Scheibel RS, Forman AD. Persistent neuro-toxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676
60. Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neu-robehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995;45:947-950
61. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon-alpha: Results from a prospective study. Eur Psychiatry 2006;21:204-210
62. Crone CC, Gabriel GM, Wise TN. Managing the neu-ropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004;71:S27-32.
63. Hilsabeck RC, Hassanein TI, Ziegler EA, et al. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005;11: 16-22.
64. Tanaka H, Maeshima S, Shigekawa Y, et al. Neuropsychological impairment and decreased regional cerebral blood flow by treatment in patients with chronic hepatitis: A preliminary study. Clin Exp Med 2006;6: 124-128
65. Valentine AD, Meyers CA, Talpaz M. Treatment of neuro-toxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995;13:561-566
66. Kraus MR, Schäfer A, Csef H, et al. Psychiatric side effects of pegylated interferon alpha-2b as compared to conventional interferon alpha-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11:1769-1774
67. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
68. Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-473
69. Maes M, Bonaccorso S, Marino V, et al. Treatment with interferon-alpha of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to interferon-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001;6:475-480
70. Wichers MC, Koek GH, Robaeys, et al. IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10:538-544
71. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: Relationship to monoamines and depression. Biol Psychiatry 2009;65:296-303.
72. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2008 May 6 [epub ahead of print].
73. Morikawa O, Sakai N, Obara H, et al. Effects of interfer-on-a, interferon-7 and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349:317-324
74. Lotrich FE, Ferrell RE, Rabinovitz M, et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-348
75. Kraus MR, Al-Taie O, Schäfer A, et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007; 132:1279-1286
76. Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amyg-dala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-834
77. Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005;62:146-152
78. Shuto H, Kataoka Y, Horikawa T, et al. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747:348-351
79. Felger JC, Alagbe O, Hu F, et al. Effects of interferon-alpha on rhesus monkeys: A non-human primate model of cytokine-induced depression. Biol Psychiatry 2007;62: 1324-1333
80. Makino M, Kitano Y, Komiyama C, et al. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br J Pharmacol 2000;130:1269-1274 (Pubitemid 30488589)
81. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: A literature review. CNS Spectr 2008;13:501-510
82. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001;105:45-55.
83. Wichers MC, Kenis G, Koek GH, et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007;62:207-214
84. Loftis JM, Wall JM, Linardatos E, et al. A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C. J Endocrinol Invest 2004;27:RC16-20.
85. Kraus MR, Schäfer A, Bentink T, et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: Interferon-induced functional androgen deficiency or depression? J Endocrinol 2005;185:345-352
86. Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E4 and neuropsychiatric symptoms during interferon alpha-treatment for chronic hepatitis C. Psychosomatics 2004;45:49-57.
87. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004;45:281-286
88. Hauser W, Zimmer C, Schiedermaier P, et al. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004;66:954-959
89. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-498
90. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571
91. Mendoza T, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196
92. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-99
93. Bech P, Bolwig TG, Kramp P, et al. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979;59:420-430
94. Bech P, Rafaelsen OJ. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiatr Scand 1980;62(Suppl 285): 128-132
95. Beck AT, Steer A. Manual for Beck Scale for Suicide Ideation. New York: Psychological Corporation; 1991.
96. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370
97. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
98. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
99. Zimmerman M, Coryell W The inventory to diagnose depression, lifetime version. Acta Psychiatr Scand 1987;75:495-499
100. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
101. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
102. Mosticoni R, Chiari G. Una descrizione obiettiva della personalità. Il Minnesota Multiphasic Personality Inventory (MMPI). Firenze, Italy: Organizzazioni Speciali, Rot Off Set; 1993:15-28.
103. Miniati M, Rucci P, Frank E, et al. Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. Psychother Psychosom 2009;78: 116-124
104. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 1988;54:1063-1070
105. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1992.
106. First MB, Spitzer RL, Williams JBW, et al. Structured Clinical Interview for DSM-IV (SCID-I) Research Version. New York: Biometrics Research, New York Psychiatric Institute; 1995.
107. Derogatis LR. SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In: Maruish M, ed. The use of psychological tests for treatment planning and outcome assessment. New York: Erlbaum; 1994:217-248
108. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
109. Spielberger CD, Gorsuch RR, Luchene RE. State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
110. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70.
111. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19:23-27
112. Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354:131-132
113. Mulder RT, Ang M, Chapman B, et al. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000;15:300-303
114. Orrù MG, Baita A, Sitzia R, et al. Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: A prospective, observational, controlled study. Epidemiol Psichiatr Soc 2005;14:145-153
115. Schäfer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon-alpha and ribavirin in psychiatric risk groups. Hepatology 2003;37: 443-451
116. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis Ctreatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007;46:991-998
117. Jakiche A, Paredez EC,Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007;102:2426-2433
118. Quarantini LC, Bressan RA, Galvão A, et al. Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007;27:1098-1102
119. Neves AC, Dickens C, Xavier M. Depression and interfer-on therapy in chronic hepatitis C patients: Epidemiology, predictive factors and proposed etiopathogenic models. Rev Port Psicossom 2005; 7:1-2.
120. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82: 175-190
121. Lang JP, Meyer N, Doffoel M. Benefits of a preventive psychiatric accompaniment in patients who are hepatitis C vírus seropositive: Prospective study concerning 39 patients [article in French]. Encephale 2003;29:362-365
122. Angelino AF, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 2005;17:471-476
123. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat 2006; 13:235-241
124. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006;57:570-572
125. Schäfer A, Scheurlen M, Weissbrich B, et al. Sustained virological response in the antiviral therapy of chronic hepatitis C: Is there a predictive value of interferon-induced depression? Chemotherapy 2007;53:292-299
126. Dalgard O, Bjøro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-49
127. Backmund M, Meyer K, Zielonka MV, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193
128. Dieperink E, Ho SB, Willenbring M. Neuropsychiatric symptoms associated with hepatitis C and interferon-alpha: A review. Am J Psychiatry 2000;157:867-876
129. Schäfer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction 2004;99:1167-1175
130. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C vírus infection to treatment with interferon a-2b. Clin Ther 2002;24:1627-1635
131. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124
132. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C- Epidemiology and management. Drugs 2006;66:155-174 (Pubitemid 43213901)
133. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211-214
134. Fireman M, Indest DW. Blackwell A, et al. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): The importance of routine mental health screening as a component of a comanagement model of care. CID 2005;40:S286-91.
135. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002:36:S210-9.
136. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002;67:117-123
137. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology 2002;36:S3-20.
138. Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries. CID 2005;40:S373-8.
139. Kresina TF, Khalsa J, Cesari H, et al. Hepatitis C virus infection and substance abuse: Medical management and developing models of integrated care-an introduction. CID 2005;40:S259-62.
140. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002;9:288-294
141. Anand B, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: Results of a national mul-ticenter study. Gastroenterology 2006:130:1607-1616
142. HoChong G. Advanced topics in hepatitis C management: Retreatment strategies for patients failing first-line therapy. (Available at www.clinicaloptions.com/Hepatitis /Management%20Series/Advanced%20HCV%20Manage ment/Modules/Retreatment%20Strategies/Pages/Page%2 01.aspx, accessed June 20, 2009).
143. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-498
144. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006;26:655-662
145. Radloff LS. The CES-D: A self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385-401.
146. Kraus MR, Schäfer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16: 1091-1099
147. Strinko JM, Di Bisceglie AM, Hoffmann JA. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: Does nursing play a role? Issues Ment Health Nurs 2004; 25:715-722
148. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000;41:439-441
149. Morasco B J, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007;103:83-90.
150. Kraus MR, Schäfer A, Schöttker K, et al. Therapy of inter-feron-induced depression in chronic hepatitis C with citalopram: A randomised, double-blind, placebo-controlled study. Gut 2008;57:531-536
151. Asnis GM, La Garza R. Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40:322-335
152. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63:194-198
153. Schramm TM, Lawford BR, MacDonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361
154. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alfa. Am J Gastroenterol 1993; 88:760-761
155. Gleason OC, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: An open-label trial of escitalo-pram. Prim Care Companion J Clin Psychiatry 2005;7: 225-230
156. Ozcanli T, Unsalver B, and Ozdemir S, et al. Sertraline-and mirtazapine-induced severe neutropenia [letter]. Am J Psychiatry 2005;162:1386.
157. Drugsite Trust. Drugs.com website: drug interactions checker. (Available at: www.drugs.com/drug-interac-tions.php).
158. Choi S. Nefazodone (Serzone) withdrawn because of hepa-totoxicity. CMAJ 2003;169:1187.
159. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002;36:S185-94.
160. Kuo A, Tan V, Lan B, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008;14:1491-1497
161. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006;37:1519-1526
162. Pol S, Bourlière M. Optimizing treatment outcomes in chronic hepatitis C: Management of non-response. Antivir Ther 2006;11:955-970
163. Van Thiel DH, Friedlander L, Molloy PJ, et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995;7:165-168
164. Van Thiel DH, Friedlander L, De Maria N, et al. Treatment of chronic hepatitis C in individuals with preexisting or confounding neuropsychiatric disease. Hepatogastroenterology 1998;45:328-330
165. Kraus MR, Schäfer A, Al-Taie O, et al. Prophylactic SSRI during interferon-alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
166. Schäfer M, Schmidt F, Grunze H, et al. Interferon alpha-associated agranulocytosis during clozapine treatment: Case report and status of current knowledge. Nervenarzt 2001;72:872-875
167. Capuron L, Hauser P, Hinze-Selch D, et al. Treatment of cytokine-induced depression. Brain Behav Immun 2002; 16:575-580
168. Gallegos-Orozco JF, Fuentes AP, Argueta JG, et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003;34:124-129